Progentos Therapeutics

Progentos Therapeutics is an early-stage biotech targeting a significant unmet need in multiple sclerosis (MS): repairing existing damage. Unlike approved immunomodulatory therapies that slow progression, Progentos aims to directly stimulate remyelination by activating oligodendrocyte progenitor cells (OPCs) through a novel, proprietary small-molecule approach. The company is in the pre-clinical stage, having identified a novel target and new chemical entities that show compelling remyelination in preclinical models, positioning it as a potential leader in regenerative neurology.

Proprietary small-molecule platform targeting a novel biological pathway to activate oligodendrocyte progenitor cells (OPCs) to drive remyelination in the central nervous system.

Progentos competes in the emerging field of remyelination therapies, which includes companies like Atara Biotherapeutics (T-cell therapy), Autobahn Therapeutics (small molecule), and pipeline programs at large pharma (e.g., Bristol Myers Squibb, Merck KGaA). Its differentiation lies in its novel target and small-molecule modality aimed at oral bioavailability and direct OPC activation.